This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Muller, S Articles by Meroni, P. Search for Related Content PubMed PubMed Citation Articles by Muller, S Articles by Meroni, P. Social Bookmarking                         What's this?

Pathogenic anti-nucleosome antibodies

CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunologie et Chimie Thérapeutiques, Strasbourg, France

J Dieker

CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunologie et Chimie Thérapeutiques, Strasbourg, France

A Tincani

Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy

PL Meroni

Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Milan, Milan, Italy

There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic chromatin component, represent both a driving immunogen and a major in vivo target for antibodies. Either a disturbed apoptosis or a reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of apoptotic nucleosomes to the immune system. These nucleosomes, which have been cleaved and modified during the process of apoptosis, escape normal clearance and encompass epitopes that normally are not encountered by the immune system. This may then lead to tolerance breaking and autoimmunity by the activation of nucleosome-specific autoreactive T cells (that help B cells) and subsequently to the production of anti-nucleosome, anti-histone and anti-DNA autoantibodies. Some anti-nucleosome antibody subsets are pathogenic and are involved in the nephritogenic process in systemic lupus erythematosus. Accordingly, several studies reported: (i) increased plasma circulating nucleosomes that positively correlated with an active disease, (ii) nucleosomes in typical glomerular deposits as well as in the basement membrane of non-lesional skin of systemic lupus erythematosus patients and (iii) a close correlation between nephritis and the presence of anti-nucleosome antibodies. Recent studies reported anti-nucleosome antibodies also in primary anti-phospholipid syndrome and particularly in patients with associated lupus-like disease.

Lupus, Vol. 17, No. 5, 431-436 (2008)
DOI: 10.1177/0961203308090030


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Faurschou, M Penkowa, C. Andersen, H Starklint, and S Jacobsen Renal cell apoptosis in human lupus nephritis: a histological study Lupus, October 1, 2009; 18(11): 994 - 999. [Abstract] [PDF]

				V Dhir, A. Singh, A Aggarwal, S Naik, and R Misra Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study Lupus, August 1, 2009; 18(9): 785 - 791. [Abstract] [PDF]